Advanced PET imaging in oncology: status and developments with current and future relevance to lung cancer care

Purpose of review This review highlights the status and developments of PET imaging in oncology, with particular emphasis on lung cancer. We discuss the significance of PET for diagnosis, staging, decision-making, monitoring of treatment response, and drug development. The PET key advantage, the noninvasive assessment of functional and molecular tumor characteristics including tumor heterogeneity, as well as PET trends relevant to cancer care are exemplified. Recent findings Advances of PET and radiotracer technology are encouraging for multiple fields of oncological research and clinical application, including in-depth assessment of PET images by texture analysis (radiomics). Whole body PET imaging and novel PET tracers allow assessing characteristics of most types of cancer. However, only few PET tracers in addition to 18F-fluorodeoxyglucose have sufficiently been validated, approved, and are reimbursed for a limited number of indications. Therefore, validation and standardization of PET parameters including tracer dosage, image acquisition, post processing, and reading are required to expand PET imaging as clinically applicable approach. Summary Considering the potential of PET imaging for precision medicine and drug development in lung and other types of cancer, increasing efforts are warranted to standardize PET technology and to provide evidence for PET imaging as a guiding biomarker in nearly all areas of cancer treatment.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: LUNG AND MEDIASTINUM: Edited by Robert Pirker Source Type: research

Related Links:

In an era highly focused on healthcare costs, can the expense of lung cancer screening be justified?Medscape Family Medicine
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care Commentary Source Type: news
The objective-response rate was 9 percent, which included one patient with a complete response and disappearance of all tumor burden, and four patients with a partial response. Of the 48 patients whose data were assessed for change in tumor size, 24 experienced a reduction of some level. Most encouraging were the patients with a higher-level of PD-L1. They had a median overall survival of 20.2 months and a 12-month overall survival of 72.5 percent. PD-L1 presence alone, though, is not considered the only factor in how well the drug would work. Other factors such as genetic mutations of the tumor and mesothelioma cell type ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Condition:   Advanced Squamous Non-small Cell Lung Cancer Intervention:   Drug: SCT200 Sponsor:   Sinocelltech Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The influence of genetic variants on natural variations in human longevity is a very complex matter. The evidence to date supports a model in which thousands of genes have individually tiny, conditional effects. Near all associations identified in any given study population have failed to appear in any of the other study populations, and effect sizes for the very few longevity-associated genes that do appear in multiple studies are not large in the grand scheme of things. These variants provide a small increase in the odds of living to be very old, but the individuals bearing them are still diminished and damaged by aging....
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Cancers, Vol. 11, Pages 107: FOSB–PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer Cancers doi: 10.3390/cancers11010107 Authors: Chen-Hung Ting Kang-Yun Lee Sheng-Ming Wu Po-Hao Feng Yao-Fei Chan Yi-Chun Chen Jyh-Yih Chen Non-small cell lung cancer (NSCLC) is among the leading causes of human mortality. One reason for high rates of NSCLC mortality is that drug resistance is a major problem for both conventional chemotherapies and less-toxic targeted therapies. Thus, novel mechanistic insights into disease pathogenesis may benefit the development of urgently needed therap...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionsGraphic health warnings and plain packaging appear to increase adolescent awareness of the dangers of tobacco use. Further research into the most effective warnings to use in combination with plain packaging is needed to ensure the greatest reduction in tobacco use and prevent tobacco-attributable morbidity and mortality in this vulnerable population.
Source: Systematic Reviews - Category: International Medicine & Public Health Source Type: research
Conclusion: We conclude that cell blocks can serve as a potential substitute for biopsies for detection of EGFR and ALK protein by immunocytochemistry, whenever patient presents with effusion and biopsy cannot be done or when tissue is not adequate.
Source: Journal of Cytology - Category: Cytology Authors: Source Type: research
Conclusion: This is the first report of immunocytochemistry of a panel of markers on cells exfoliated in sputum samples which suggests that analysis of immunocytochemical markers in sputum samples can be attempted as a cost-effective and reliable predictor of prognosis and survival. Accumulation of mutated p53, overexpression of galectin-3, and lower expression of p16 and EGFR proteins were found to predict poor prognosis for lung cancer.
Source: Journal of Cytology - Category: Cytology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Mergers and Aquisitions